Shopping Cart
- Remove All
- Your shopping cart is currently empty
Crotedumab (REGN1193) is a humanized antibody targeting GCGR, which reduces fasting blood glucose and improves glucose tolerance, used in diabetes research.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $197 | In Stock | |
5 mg | $516 | In Stock | |
10 mg | $828 | In Stock | |
25 mg | $1,230 | In Stock | |
50 mg | $1,650 | In Stock |
Description | Crotedumab (REGN1193) is a humanized antibody targeting GCGR, which reduces fasting blood glucose and improves glucose tolerance, used in diabetes research. |
Targets&IC50 | GCGR:0.1 nM (Kd) |
In vitro | Crotedumab inhibits glucagon-induced signaling in transfected human, monkey, mouse, and rat HEK293 cells via GCGR with IC50 values of 0.65, 3.2, 0.94, and 1.0 nM, respectively.[1] |
In vivo | Administration of Crotedumab (a single subcutaneous injection) to diabetic OB/OB and diet-induced obese mice reduced blood sugar to levels observed in GCGR deficient mice. In diet-induced obese mice, Crotedumab reduced food intake, adipose tissue mass, and body weight. A single administration of Crotedumab in diabetic cynomophagus monkeys normalized fasting blood sugar and glucose tolerance, and increased circulating levels of glucagon and amino acids. [1] |
Alias | REGN1193, REGN 1193, Anti-GCGR Reference Antibody |
Cas No. | 1452387-69-7 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.